Molecular Detection of Circulating Cancer Cells in Breast, Ovarian, Colon and Pancreatic Cancer
OBJECTIVES:
- To assess frequency of circulating tumor cells (CTCs) in patients with metastatic
ovarian, breast, pancreatic, and colon cancers.
- To assess the variability in number of CTCs between patients with the same tumor type.
- To correlate the number of CTCs with extent of tumor burden as measured by tumor
markers, imaging, and the number of metastatic sites and proliferation and apoptotic
markers.
OUTLINE: Blood samples are collected before treatment and analyzed using molecular detection
techniques to detect circulating cancer cells. Samples are assessed by immunofluorescence
for markers of proliferation and survival (e.g., EGFR, phosphorylated EGFR, AKT,
phosphorylated AKT, cytokeratins, MAPK, Src, and FAK).
Observational
Observational Model: Cohort, Time Perspective: Prospective
Frequency of circulating cancer cells (CTC)
1 day
No
Charles Erlichman, MD
Principal Investigator
Mayo Clinic
United States: Federal Government
CDR0000582085
NCT00898781
November 2007
April 2010
Name | Location |
---|---|
Mayo Clinic | Rochester, Minnesota 55905 |